1537-2995/asset/olbannerleft.gif?v=1&s=05048e38d3df7bca9b579f6801d4ffb0d1f36a40)
1537-2995/asset/olbannerright.gif?v=1&s=80a40f0b52bfb45a42076cd036b6ddb39ff98029)
In vivo neutralization of anti-A and successful transfusion of A antigen–incompatible red blood cells in an animal model
Article first published online: 20 MAY 2011
DOI: 10.1111/j.1537-2995.2011.03184.x
© 2011 American Association of Blood Banks
Additional Information
How to Cite
Oliver, C., Blake, D. and Henry, S. (2011), In vivo neutralization of anti-A and successful transfusion of A antigen–incompatible red blood cells in an animal model. Transfusion, 51: 2664–2675. doi: 10.1111/j.1537-2995.2011.03184.x
Publication History
- Issue published online: 12 DEC 2011
- Article first published online: 20 MAY 2011
- Received for publication December 12, 2010; revision received March 17, 2011, and accepted March 24, 2011.
- Abstract
- Article
- References
- Cited By
BACKGROUND: Our aim was to determine if the historical principle of Lewis glycolipid neutralization of antibody and subsequent Lewis-incompatible transfusion could be extended and applied to the ABO blood group system using synthetic glycolipid-like constructs.
STUDY DESIGN AND METHODS: In vitro experiments with human blood and blood group A function-spacer-lipid constructs (FSL-A) were used to determine rates and concentrations that caused antigen transformation and anti-A neutralization. FSL-A constructs were intravenously infused into naive and anti-A–immunized mice to determine in vivo antigen transformation, anti-A inhibition, and tolerance to A antigen–incompatible transfusions (A+biotin kodecytes).
RESULTS: FSL-A was able to cause in vivo transformation of circulating mouse cells into A antigen–positive cells (in vivo A kodecytes) without consequence in animals either with or without circulating anti-A. FSL-A was able to neutralize circulating anti-A and allow for successful transfusion of incompatible A kodecytes. In the absence of FSL-A neutralization incompatible cells were rapidly destroyed.
CONCLUSIONS: FSL constructs have the potential to neutralize circulating antibodies and allow for, or mitigate, the consequences of ABO-incompatible red blood cell transfusion.